From: Value assessment of artificial intelligence in medical imaging: a scoping review
Element in study | Categories | Frequency (%) |
---|---|---|
Country of 1.author | Australia | 3 (3%) |
Asia and the Middle East (China, Hong Kong, India, Israel, Japan, Saudi Arabia, Singapore, South Korea) | 16 (19%) | |
Canada | 6 (7%) | |
Europe (Cyprus, Denmark, Finland, France, Germany, Italy, Netherland, Portugal, Spain, Sweden) | 23 (27%) | |
UK | 8 (9%) | |
US | 26 (30%) | |
Unclear | 1 (1%) | |
Other (Norway, Switzerland) | 3 (3%) | |
Clinical area covered | Breast cancer (mammography and digital breast tomosynthesis) | 9 (10%) |
Dementia/Alzheimer´s disease/neuroimaging | 7 (8%) | |
Dermatology (melanoma diagnosis, histopathologic images) | 2 (2%) | |
Cardiovascular disease (cardiovascular imaging, coronary artery disease) | 8 (9%) | |
Diabetes and ophthalmology (ocular imaging, diabetic retinopathy screening, diabetic eye disease screening) | 6 (7%) | |
Oncology and radiotherapy | 8 (9%) | |
Radiology | 15 (17%) | |
Radiomics | 11 (13%) | |
Medical imaging | 12 (14%) | |
Pathology (histopathology images) | 2 (2%) | |
Other | 6 (7%) | |
Study type | Actual evaluation | 15 (17%) |
Guidelines, statements or frameworks | 10 (12%) | |
Reviews, surveys or papers voicing future needs or challenges | 61 (71%) | |
Year of publication | 2016 | 0 (0%) |
2017 | 11 (13%) | |
2018 | 9 (10%) | |
2019 | 37 (43%) | |
2020 (mid-September) | 29 (34%) | |
Domain mentioned or perceived relevant | 1. The health problem and current use of technology | 55 (64%) |
2. Technology aspects | 63 (73%) | |
3. Safety assessment | 17 (20%) | |
4. Clinical effectiveness, e.g. clinical outcomes | 39 (45%) | |
5. Economics | 52 (60%) | |
6. Ethical analysis | 25 (29%) | |
7. Organisational aspects | 53 (62%) | |
8. Patients and social aspects | 33 (38%) | |
9. Legal aspects | 43 (50%) | |
10. Development of AI algorithm, performance metrics and validation | 67 (78%) | |
11. Other aspects | 2 (2%) |